- Home
- URGN vs MUX Comparison
URGN vs MUX Comparison
Compare URGN & MUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MUX
- Stock Information
- Founded
- URGN 2004
- MUX 1979
- Country
- URGN United States
- MUX Canada
- Employees
- URGN N/A
- MUX N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MUX Precious Metals
- Sector
- URGN Health Care
- MUX Basic Materials
- Exchange
- URGN Nasdaq
- MUX Nasdaq
- Market Cap
- URGN 547.1M
- MUX 443.5M
- IPO Year
- URGN 2017
- MUX N/A
- Fundamental
- Price
- URGN $11.33
- MUX $8.41
- Analyst Decision
- URGN Strong Buy
- MUX Strong Buy
- Analyst Count
- URGN 5
- MUX 2
- Target Price
- URGN $44.50
- MUX $15.63
- AVG Volume (30 Days)
- URGN 351.4K
- MUX 507.9K
- Earning Date
- URGN 11-06-2024
- MUX 11-05-2024
- Dividend Yield
- URGN N/A
- MUX N/A
- EPS Growth
- URGN N/A
- MUX N/A
- EPS
- URGN N/A
- MUX 2.07
- Revenue
- URGN $89,363,000.00
- MUX $199,634,000.00
- Revenue This Year
- URGN $13.39
- MUX $22.76
- Revenue Next Year
- URGN $45.06
- MUX $18.67
- P/E Ratio
- URGN N/A
- MUX $4.07
- Revenue Growth
- URGN 15.64
- MUX 47.02
- 52 Week Low
- URGN $10.60
- MUX $5.92
- 52 Week High
- URGN $20.70
- MUX $12.50
- Technical
- Relative Strength Index (RSI)
- URGN 37.97
- MUX 44.96
- Support Level
- URGN $11.10
- MUX $8.55
- Resistance Level
- URGN $13.13
- MUX $9.17
- Average True Range (ATR)
- URGN 0.53
- MUX 0.36
- MACD
- URGN -0.10
- MUX 0.02
- Stochastic Oscillator
- URGN 12.15
- MUX 24.89
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MUX McEwen Mining Inc.
McEwen Mining Inc is a mining and minerals production and exploration company focused on precious and base minerals in Argentina, Mexico, and the United States. The company's overall revenue is principally derived from the production of gold and silver. The company owns and operates the wholly-owned El Gallo 1 mine in Mexico, and has a minority shareholding in the company that operates the San Jose mine in Argentina. More than half the company's gold output is produced by the El Gallo 1 mine. The remaining gold production, and the majority of silver production, is produced by the San Jose mine. Geographically, the majority is from Canada.